Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Inspire Medical to $330 from $315 and keeps an Overweight rating on the shares. The firm notes the company reported Q2 Sales that beat expectations, driven by higher utilization at existing centers. The company also raised sales guidance by $20M at the midpoint and submitted Inspire V to the FDA.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Inspire Medical price target raised to $350 from $305 at Lake Street
- Inspire Medical price target raised to $405 from $395 at UBS
- Inspire Medical raises FY23 revenue view to $600M-$610M from $580M-$590M
- Inspire Medical reports Q2 EPS (41c), consensus (57c)
- Inspire Medical Systems, Inc. Announces Second Quarter 2023 Financial Results and Updates 2023 Outlook